DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lescol (Fluvastatin Sodium) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

LESCOL SUMMARY

Lescol®

Lescol® (fluvastatin sodium), is a water-soluble cholesterol lowering agent which acts through the inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase.

Therapy with lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see National Cholesterol Education Program (NCEP) Treatment Guidelines, below).

Lescol® (fluvastatin sodium) and Lescol® XL (fluvastatin sodium) are indicated to reduce elevated total cholesterol (Total-C), LDL-C, TG and Apo B levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures has not been adequate.

In patients with coronary heart disease, Lescol and Lescol XL are indicated to reduce the risk of undergoing coronary revascularization procedures.

Lescol and Lescol XL are also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total and LDL cholesterol to target levels.

Therapy with lipid-altering agents should be considered only after secondary causes for hyperlipidemia such as poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other medication, or alcoholism, have been excluded.
See all Lescol indications & dosage >>

LESCOL NEWS HIGHLIGHTS

Media Articles Related to Lescol (Fluvastatin)

VAP(R) Cholesterol Test Helps Researchers Identify Treatment Effects Of Combination Therapy
Source: Cholesterol News From Medical News Today [2008.11.11]

more >>

Published Studies Related to Lescol (Fluvastatin)

Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease. [2008.09]

Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double-blind, placebo-controlled trial. [2008.07.15]

Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers. [2008.05.06]

Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. [2007.09]

Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: a pooled analysis of thirty clinical trials. [2007.09]

more >>

Clinical Trials Related to Lescol (Fluvastatin)

Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-Menopausal Women With Low Bone Mass [Completed]

Efficacy and Safety Study of Fluvastatin and Ezetimibe Combined Versus Fluvastatin Alone [Completed]

A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers [Recruiting]

Evaluation of the Effect of Fluvastatin 40 mg (b.i.d.) in the Prevention of the Development of Vasculopathy of the Graft in de Novo Renal Transplant Patients Transplant [Completed]

The Effect of Fluvastatin Treatment in Patients With Metabolic Syndrome [Completed]

more >>

Page last updated: 2008-11-11

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008